

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A01N 1/02	A1	(11) International Publication Number: WO 91/09520 (43) International Publication Date: 11 July 1991 (11.07.91)
(21) International Application Number: PCT/US90/07569 (22) International Filing Date: 20 December 1990 (20.12.90) (30) Priority data: 455,562 21 December 1989 (21.12.89) US 455,580 21 December 1989 (21.12.89) US (71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 300 Lakeside Drive, 22nd Floor, Oakland, CA 94612-3550 (US). (72) Inventor: WIKMAN-COFFELT, Joan ; 1610 Redwood Street, Davis, CA 94965 (US). (74) Agent: DOLEZALOVA, Hana; Phillips, Moore, Lempio & Finley, 177 Post Street, Suite 800, San Francisco, CA 94108 (US).		(81) Designated States: AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CM (OAPI patent), DE, DE (European patent), DK, DK (European patent), ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL, NL (European patent), NO, RO, SD, SE, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent). Published <i>With international search report.</i>
(54) Title: NOVEL AND IMPROVED TECHNOLOGY FOR PRESERVATION OF ORGANS FOR TRANSPLANTATION		
(57) Abstract A novel method for long-term preservation of organs for transplantation wherein the organ to be transplanted is first perfused with a preservation solution containing essentially pyruvate, inorganic salts providing ions to retain the cell action potential across the membrane and optionally a protein. Then, the organ is perfused with the second preservation solution containing the first solution and alcohol.		

- 1 -

NOVEL AND IMPROVED TECHNOLOGY FOR PRESERVATION
OF ORGANS FOR TRANSPLANTATION

5 Technical Field

This invention concerns a novel and improved process, for long-term preservation of organs for transplantation. The preservation process comprises perfusing the organs such as heart, liver, kidney, pancreas, spleen, brain, embryo, 10 testicles, ovaries, lung or heart-lung complex, or washing organs such as cornea, skin or cartilage, with a first novel physiological preservation solution containing pyruvate, under normal physiological conditions and at a warm temperature to remove blood and other impurities and debris 15 by the increased flow through the organ, bringing the organ to its basal metabolic rate stage with a second preservation solution containing pyruvate and a small percentage of alcohol and preserving the organ with diffusion of gases and nutrients from the media, by submerging and storing the 20 organ in the first preservation solution at low but not freezing temperature for periods longer than 24 hours.

Disclosure of Invention

One aspect of this invention is a novel and improved process for long-term preservation of organs, particularly 25 the heart, liver, kidney, spleen, heart-lung, pancreas, cartilage, skin and cornea for transplantation.

Other aspect of this invention is the preservation of the organ for period 24 hours or longer wherein at that time the organ recovers 90-100% of its original functional 30 activity and around 70% of its intracellular mitochondrial metabolic activity.

Another aspect of this invention is preservation of the organs by sequence of events including a perfusion or washing of the organ, at a warm temperature, with the first 35 preservation solution containing pyruvate for removal of the

- 3 -

Figure 2 is a diagrammatic representation of liver preservation conditions.

Figure 3 depicts ventricular pressure for the heart perfused by cardioplegic solutions in pre-ischemic and post-ischemic hearts.

Figure 4 depicts NMR spectra of hearts pre-ischemic and post-ischemic baseline energy level.

Figure 5 is a diagrammatic representation of kidney preservation apparatus with continuous perfusion.

Figure 6 is a model of the apparatus useful for perfusion of the organs.

Best Mode of Carrying Out the Invention

This invention concerns a novel and improved process for long-term preservation of the organs for transplantation. The preservation process comprises the following steps.

The organ is perfused at a warm temperature with a first preservation solution containing pyruvate to vasodilate, remove blood, increase flow, and load the cells with an energy supply in the form of a clean substrate, namely pyruvate. Pyruvate prevents edema, ischemia, calcium overload, and acidosis. It also helps preserve the action potential across the cell membrane.

Cannulation of the primary artery or vein incoming to the organ allows for a more complete exchange of gas, substrate, and media during perfusion and storage, thus allowing for usage of pyruvate as an energy source.

Perfusion with a second preservation solution containing both pyruvate and alcohol slows the organ's metabolism, but preserves the energy state of the organ.

Storage of the organ allows the organ to be kept in a closed aseptic container for transportation under conditions which permit diffusion of gases and media during the interim (24 hour or longer) period of transfer while all the time retains the organ in a healthy viable state. Unlike with

- 5 -

as needs be, and a slow influx of oxygen during the preservation period. For extended period of time over 24 hours, the preservation solutions medium contains additional nutrients enabling the basal metabolism to proceed to assure the organ recoverability at the end of preservation period and before a transplantation.

The unique properties of the process are (a) perfusing or washing the organ with a first novel preservation solution (Solution C) containing a pyruvate, protein such as albumin or fetal calf serum and ethylenediaminetetraacetic acid (EDTA), at a warm, preferably room temperature, to remove blood and metabolites from the organ, to load the cells with pyruvate, and to increase the flow of the perfusate through the circulation; (b) serially perfusing the organ with a second novel preservation solution (Solution A) comprising the first solution and a small percentage preferably between 0.01-6%, most preferably around 0.1-4% of ethanol to bring about the reversible decrease in metabolism to the basal metabolic level, prevent edema and retain the integrity of the vascular bed, said perfusion also being performed at a temperature between 4-37°C; and (c) submerging the organ having cannulated primary incoming vein, when appropriate, to allow for diffusion of gases and preservation media, into the large volume of the first solution C for the entire preservation period. The preservation step is maintained at temperature between 2-10°C, preferably for at 4°C for the entire period of the organ preservation.

Unique properties of the preservation solutions are: (a) a presence of pyruvate as a substrate for energy supply demands substituting for generally used glucose which leads to the metabolic acidity and edema causing the damage to the organ function; (b) a presence of protein such as albumin or fetal calf serum useful for cellular recovery and tissue renewal; (c) absence of glucose as an energy source; (d)

- 7 -

a physiological state. Sodium chloride is used to balance the osmolarity and retain the action potential across the cell membranes.

As has been discussed above, while the source of energy for the continuous organ activity is necessary even if the organ is in basal metabolic state, it has been found that glucose, which was predominantly used as a source of energy in currently available preservation solutions, causes the acidosis and edema of the tissue which subsequently result in the impairment of the normal function of the tissue. Glucose and fatty acids are more deleterious to the organ during ischemia due to build up of by-products, including accumulation of sugar phosphates. Pyruvate, on the other hand is a beneficial substrate protecting the organs against ischemia, acidosis, edema and a calcium overload. These fundamental observations led to current formulation of a saline solution with pyruvate as the substrate and to the current finding that by substituting glucose in the preservation solution with pyruvate, the tissue acidosis and edema does not occur. Moreover when such solution is combined with alcohol as an agent to arrest the metabolism, a beneficial preservation solution suitable for long-term preservation of the organ results. The discovery described here indicates that using, in certain sequence, the preservation and cardioplegic solutions containing pyruvate, and pyruvate plus ethanol, is able to protect the organ's function for a 24 hour period or longer.

In the absence of work, the organs are able to survive in, and utilize a basal energy state because there is normally an excess concentration of high energy phosphate present in the cells. It appears that when the organ is in a dysfunctional state, the diffusion of oxygen from the oxygenated media is sufficient to maintain the basal energy state of the organ. This occurs at a reduced energy level, but substrate still may be necessary to maintain a viable

- 9 -

Cross, Japan, preferably in emulsified form.

In another embodiment, the preservation solutions may additionally contain individual essential amino acids or mixtures thereof, or be completely substituted with Eagle or 199 media obtained, for example, from Gibco Laboratories.

Procedure for Organ Preservation

Heart 30 with cannulated aorta, pulmonary artery and with introduced micromanometer catheter in the left ventricle (Fig. 1C) is connected to the perfusion chamber 20 connected to container 40 containing solution C and container 50 containing solution A, both being regulated with valves 42 and 52 respectively (Fig. 6). In alternative, liver 30, with cannulated portal vein or any other organ having canulates supply vein (Fig. 2A) is submerged in the perfusion chamber 20 as above. Each container has build-in thermistor to enable to preset and maintain certain temperature. Perfusion by the solution C or A then proceeds. The perfusion with solution C containing pyruvate is designed to bypass the glycolytic pathway and to substitute for glucose as an energy substrate.

Glycolysis in the cells is partially rate-limited by phosphofructokinase, which is inhibited by intracellular calcium $[Ca^{2+}]_i$ and hydrogen ions $[H^+]_i$ and activated by cAMP. $[H^+]$ and $[Ca^{2+}]_i$ are augmented in ischemia. When glucose was used as the only substrate in the preservation solution $[NADH]/[NAD]$, the phosphorylation potential and developed pressure were significantly lower and concentrations of phosphomonoester sugars and hydrogen ions $[H^+]_i$ were significantly higher in isolated cardiomyopathic organs as compared to normal organs. Pyruvate on the other hand was shown to lower $[Ca^{2+}]_i$. The results published in Basic Res. Cardiol., (1990), suggest that cellular ischemic failure is partially due to calcium and/or hydrogen ion-induced inhibition of glycolysis, which is alleviated by bypassing the glycolytic pathway with pyruvate.

- 11 -

around 10 minutes at temperatures from 2°C to 37°C. Higher temperatures than 28°C are preferred because they allow for vasodilation but when the circumstances require, the temperature may be lowered to about 4°C which will further
5 slow down metabolism but more importantly will cause certain degree of vasoconstriction. The perfusion with the cold solution containing potassium chloride is preferably done at low temperatures around 4°C.

In alternative, the organ preservation according to the
10 procedure of this invention can be successfully accomplished by perfusion with solution C at warm temperatures (24-37°C) and by subsequent cooling of the solution A to temperatures between 2-10°C, preferably to 4°C. This temperature is also used for the storage period for this procedure wherein the
15 organ cannulated with cannula intact is transferred to the container depicted in Fig. 1B. The only requirements for the container are that it is tightly closed, filled with enough of solution C in such quantity, usually between 3-8 liters, which allows complete submerging of the organ with
20 cannula in the solution, that the aseptic conditions can be preserved including the aseptic supply of gas, preferably oxygen/carbon dioxide 95/5%, and the temperature maintained around 4°C. In alternative, the container may be equipped with the perfusion pump and the organ may be continuously
25 perfused with solution C at temperature between 2-8°C, preferably around 4°C or any other temperature which is needed for its preservation.

Using the procedure of this invention, the organ may be successfully preserved from 24 hours to seven or more days
30 provided that the constant supply of oxygen and essential energy substrate and nutrients is provided. Following the period of preservation but before the organ is transplanted, it may be re-perfused with the solution C to restore its normal physiological functions.

35 Additional agents, such as drugs, hormones, vitamins

- 13 -

in preischemia, during the contractions of the heart the pressure returns to 0 levels. Both end-diastolic pressure and coronary flow are the same with heart rate slower and oxygen consumption slightly lower in postischemia. Standard solution B, which has no pyruvate and no alcohol, shows 5 drastical reduction in heart contractility, wherein the postischemic heart contracts only somewhere between 40-70 mm Hg instead of 0-160 as seen in preischemic heart. The results in Table I support these findings. Developed 10 pressure, coronary flow, heart rate and oxygen consumption are all much lower, with end diastolic pressure much higher and the heart looks healthy and normal. On the contrary, the heart stored in standard solution B was edemic and ischemic, probably due to too much of Ca^{++} and lack of 15 available energy substrate, and its function was only about 50%.

Figure 4 A, B and C shows representative ^{31}P -NMR spectra of hearts preischemic (baseline energy level) and postischemic (30 min reperfusion following 24 hours storage) 20 for hearts perfused in solution A (A), solution B (B), and solution C (C).

The upper lower spectra show the preischemic spectra, the upper spectra are postischemic. When the energy level is about the same, the spectra look the same. As seen from 25 spectra A, both upper and lower spectra are about identical, while spectra B, showing the energy level after 24 hours storage in Roe Standard solution (solution B), shows the presence of large amount of inorganic phosphate evidencing intracellular inequilibrium and intracellular acidity. ATP 30 and creatinephosphate (PCr) are grossly diminished when the solution C was used without alcohol, depletion in energy supply is also seen because the heart was not put into the basal metabolic rate state and there was not sufficient supply of energy substrate to support full heart metabolism. 35 The spectra in Figure 4 are confirmed by results summarized

- 15 -

are well documented. Although the most commonly used preservation solution is a cold potassium chloride solution, advantages of warm, oxygenated blood solution were described in J. Thorac. Cardiovasc. Surg., 91:888 (1986). In this invention, perfusing the organ with solutions at warm temperature was found beneficial since it allowed flushing of the veins and organ vessels and prevented them from collapsing. It was also found to be important to remove all blood from the organ since the breakdown of hemoglobin releases, among other things, iron which may have deleterious effects on clotting and inhibition of enzymes.

The perfusion of the organ with the solution A effectively stops the organ work and induces the basal energy state. At this state, in which the organ is in the basal state, as evidenced by the diminished metabolism measured by biochemical techniques known in the art, and having canula/cannulae intact and opened, the organ is transferred to the storage container filled with solution C and maintained at temperature between 2°C-10°C, preferably about 4-15°C. Container can be of any size and shape as long as it contains at least 4-8 liters of solution C so that the cannulated organ including open ends of canulae are submerged at all times in the solution C. One example of such container is shown in Figures 1B and 2B. It is important that the container are that is tightly capped and is equipped to provide slow but continuous influx of oxygen. The container and a solution therein must both be sterile and the influx of oxygen must be done aseptically. The cannulation tubes are provided and are necessary for continuous aeration by diffusion of the cell and tissues while in the storage container. The cannulation tubes are designed so that the physician performing transplantation can connect the cannula to a pressure transducer in order to check pressure in the organ or other parameters before transplanting.

- 17 -

preferably 4°C.

In alternative, the organ is first perfused with a warm solution C (35-37°C) and when all blood and tissue debris is rinsed out, the perfusate is cooled down and the organ is stored, as above, in the cold solution C at temperature of 4°C. In yet another alternative, the organ is first perfused with solution C at warm temperature and then transferred into cold solution A at about 4°C. Optionally, oxygen carriers such as various fluorocarbons, for example perfluorocarbon in amount from 5-20% can be added to the solution C, A or both. In this instance, the fluorocarbon will be emulsified with for example lecithin, using methods known in the art.

Another alternative contemplated to be within preview of this invention is the replacement of the solution C or solution A with the liquid media, such as Medium 199, available from GIBCO Laboratories, New York, which consist of mixture of essential amino acids, as long as the medium is either mixed with or prepared with the pyruvate in amount from 1-20 mM, preferably in amount 6-12 mM. These medium/pyruvate solutions will be particularly useful for preservation of organs for longer than 24 hours period of time and mainly for preservation of heart, heart-lung, brain and embryo.

In yet another alternative, the solution C or medium/pyruvate combination may be used for continuous perfusion of the organ in the storage chamber. In such practice a portable miniature perfusion pump is connected to the container aseptically and connected to the cannulated organ. The organs are then continuously perfused with medium/pyruvate containing solutions C or A for the whole period of preservation and storage.

Use of alcohol as a preservation solution may have limited use for transplantation unless the alcohol is perfused out of the organ system prior to use. Thus, it is

- 19 -

EDTA, 1.2 mM (144 mg) of magnesium sulfate, 10 mM (1.1 g) of sodium pyruvate, 0.1% 1. of fetal calf serum and 4% of ethanol were dissolved at room temperature under constant stirring in 1 liter of deionized distilled sterile water, pH was adjusted to 7.4, and the solution was stored in the refrigerator at 4°C until used for heart perfusion.

Solution B

20 mEq/l of potassium (K^+), 27 mEq/l of sodium (Na^+), 3 mEq/l of magnesium (Mg^{2+}), 47 mEq/l of chloride (Cl^-) was dissolved in 1 liter of deionized water. The solution was adjusted to osmolarity 347 and pH 7.6 and stored at 4°C in the refrigerator. The preparation of this solution is described in J. Thorac. Cardiovasc. Surg., 73:366 (1977).

Solution C

1.07 mM (6.25 g) of sodium chloride, 4.3 mM (320 mg) of potassium chloride, 2.0 mM (294 mg) of calcium chloride, 1.2 mM (144 mg) of magnesium sulfate, 25 mM (2.1 g) of sodium bicarbonate, 0.5 mM (146 g) of sodium EDTA and 10 mM (1.1 g) of sodium pyruvate were dissolved, under constant stirring in 1 liter of deionized water, pH was adjusted to 7.4, and the solution was stored at 4°C in the refrigerator. Before use, solutions were oxygenated with mixture of 95/5% of oxygen/carbon dioxide.

EXAMPLE 2

Testing of Cardioplegic Solutions

This example illustrates testing and effect of cardioplegic solutions on the heart preservation.

Animal hearts were obtained from Golden hamsters weighing approximately 140 grams and 18 months of age. The animals were anesthetized with ether. After midline sternotomy the heart was rapidly excised with removal of the pericardium, immediately connected to an aortic perfusion cannula and perfused by a modified Langendorff method described in Am. J. Physiol., 245:H 354 (1983) with a perfusion pressure of 140 cm H_2O . The oxygenated perfusate

- 21 -

phosphate, phosphocreatine and phosphate groups of adenosine triphosphate (ATP) were identified. Intracellular pH was standardized as follows: A standard solution at physiological ionic strength (150 mM KCl, 8 mM ATP, 10 mM PCr, 5 mM Pi, and 9 mM MgSO₄) was used at a temperature of 37°C to obtain the chemical shift titration curve of pH dependent Pi to PCr peak difference; this curve was fitted to the Henderson-Hasselback equation. Phosphate peaks were quantitated using manual electronic planimetry and estimated for whole heart detection by comparison to a capillary tube of standard methylene diphosphonic acid fixed inside the NMR tube. High energy phosphate values determined by ³¹P-NMR were standardized by parallel studies of high pressure liquid chromatography of freeze-clamped tissue Cardiovasc. Res., 20:471 (1986).

After the hearts were perfused with a Krebs-Henseleit solution physiological as well as biochemical measurements performed, the heart was transferred to solution A, solution B or solution C as described in Example 1.

The hearts were perfused for 10 minutes with one of the three solutions. Then, the cannula feeding the aorta was clamped, the cannulae leading to the aortic perfusate and to the pressure transducer were disconnected, and the heart submerged in one of the three respective solutions at 4°C. The details are depicted in Figure 1. It was important that both cannulae were open during the 24 hours of storage for interchange with perfusate and dissolve O₂ in the perfusate. It was also important that no air entered the chamber during this time. After 24 hours of storage at 4°C, the cannulated hearts were again reperfused in a normal Krebs Henseleit medium. For reperfusion the cannula leading to the submerged aorta was clamped and placed in position of the perfusion apparatus. The cannula leading to the left ventricular chamber was again fastened into position.

The stimulator-triggered freeze clamp was attached to

- 23 -

the three solutions described in Example 1. Both canulae were left open to assure the interchange with the perfusate solution and the supply of oxygen from the perfusate via cannulae into the heart. The ischemic period was 24 hours. After 24 hours of storage at 4°C, the cannulated hearts were again reperfused with a normal Krebs-Henseleit medium.

Preischemic, postischemic and control values were then determined and are summarized in Table I.

Preischemic and postischemic cardiac function is shown in Table I for all three groups. Prior to ischemia, among all three groups there was no significant difference in developed pressure, end-diastolic pressure, coronary flow, heart rate and consumption prior to ischemia. In postischemia as compared to preischemia, Group I showed no significant difference in developed pressure, end-diastolic pressure and oxygen consumption, however, there was a small but significant ($p < .05$) decrease in coronary flow, heart rate and the rate-pressure product. Group II, on the other hand, showed a significant ($p < .01$) decrease in all measured hemodynamic parameters, except end-diastolic pressure; in latter there was a significant ($p < .001$) increase in pressure. In Group III there was a significant ($p < .01$) decrease in heart rate, rate-pressure-product, and O_2 consumption, but no significant change in developed pressure, coronary flow and end-diastolic pressure. Between Groups I and III, there was no significant difference in end-diastolic pressure, coronary flow, developed pressure and heart rate, postischemically, however the rate-pressure-product and O_2 consumption were moderately but significantly smaller ($p < .05$) in Group III as compared to Group I. Group II postischemically had a significantly ($p < .01$) lower developed pressure, coronary flow, rate-pressure-product and O_2 consumption as compared to Groups I and III, and a significantly ($p < .001$) higher end-diastolic pressure. Representative tracing of left ventricular

- 25 -

- I is developed pressure in mm Hg
II is end diastolic pressure mm Hg
III is coronary flow ml/min
5 IV is heart rate (BPM)
V is rate pressure product [$\times 10^3$]
VI is Oxygen consumption μ moles/g/day weight/min

EXAMPLE 4

Preischemic and Postischemic Energy Levels

10 This example illustrates the preischemic and postischemic energy levels depending in the cardioplegic solution used.

In the same three groups of isolated hamster hearts as described in Example 3, levels of ATP, phosphocreatine, 15 inorganic phosphate [Pi] and intracellular pH [pH]_i were determined. The results are summarized in Table II.

Preischemic and postischemic energy levels are shown in Table II. It was necessary to measure preischemic energy levels by ³¹P-NMR which is non-invasive so that the hearts 20 would be available for further study. Standardized values obtained from ³¹P-NMR matched freeze clamped data. The NMR values were normalized and then standardized by parallel freeze clamped data. It was necessary to freeze-clamp in order to obtain the postischemic values since the energy 25 levels were low at this time and difficult to detect by ³¹P-NMR in the small hamster hearts (approximately 0.6 grams). It was possible, however, to obtain the inorganic phosphate and [pH]_i from the ³¹P-NMR data. The inorganic phosphate did not rise excessively high since there was no added phosphate 30 in the perfusate. Preischemically there was no significant difference in the energy metabolites among the three groups of animals, nor any difference in [pH]_i. Postischemically there was no significant difference in ATP and P_i among the three groups of animals (Table II). On the other hand, PCr 35 was significantly higher in Groups 1 (p<.001) and 3 (p<.01)

- 27 -

a slightly alkaline $[pH]_i$. The latter may be due to leaky membranes and inability of the myocardial fibers to maintain the ion gradient. Rapid reversibility of cardiac depression is a desirable feature of a cardioplegic solution. The 4% alcohol caused an immediate arrest and the cardiac depression induced by alcohol was immediately reversible. An immediate arrest may not be crucial for preserving cardiac function since myocardial recovery was nearly as good with the physiological saline having pyruvate as the substrate, as compared to the same solution plus alcohol, and significantly better than a standard cardioplegic solution.

High intracellular calcium $[Ca^{2+}]_i$ and low $[pH]_i$, which occurs with ischemia, inhibits glycolysis and fatty acid oxidation, resulting in accumulation of intermediates with no provision for synthesis of high energy phosphates. With reperfusion the PCr levels rose in the hearts of the groups which were provided pyruvate. Commensurate with the rise in PCr there was also an increase in oxygen consumption. Inorganic phosphate did not rise excessively high in any of the three groups; the latter is most likely due to the fact that no inorganic phosphate was added to the media.

The results of this study confirm that a saline solution containing 4% ethanol and 10 mM pyruvate preserves cardiac function over a 24 hour period, and that a saline solution containing 10 mM pyruvate partially preserves cardiac function over a 24 hour period.

- 29 -

transportation from the one room to another. After 24 hours, the heart with both cannulae was removed from the container, reattached to the isolated heart apparatus and reperfused with the solution C again. The vital signs were followed.

At that time, more than 90 % of the normal cardiac function of the myocardium and more than 70% of the mitochondrial activity was restored, measured by pressure, heart beat, coronary flow and ECG and ^{31}P -NMR.

10

EXAMPLE 6

Preservation of Isolated Liver for Transplantation

This example illustrates the long-term preservation of liver for transplantation.

A. The portal vein and the bile duct of the rat liver are cannulated, removed, transferred to perfusion chamber and perfused 10 minutes with the physiologic solution at 37°C. The perfusion is then switched to the solution A described in Example 1 and perfused for 10 minutes at 37°C temperature for another 10 minutes. Samples and the level of transaminases are determined to show the degree of liver function. After 10 minutes, the perfusion is disconnected and the liver are submitted to ^{31}P -NMR analysis as described in Example 2.

Liver is then transferred to the storage container filled with solution A and maintained at 4°C as shown in Figure 1B. Care is taken that the portal cannula is completely submerged.

Prior to the organ transfer, the container is preoxygenated with filtered mixture of oxygen and carbon dioxide 95/5% from the gas tank source kept outside of container. The container and the solution are kept aseptic at any time.

The liver are gently submerged in the solution A and stored for 24 hours. After 24 hours, liver is removed and the biochemical, enzymatic tests are performed and

- 31 -

Kidney is then transferred to the storage container filled with solution A and maintained at 4°C as shown in Figure 1B. Care is taken that the renal cannula is completely submerged.

5 Prior to the organ transfer the container is preoxygenated with filtered mixture of oxygen and carbon dioxide 95/5% from the gas tank source kept outside of container. The container and the solution are kept aseptic at any time.

10 The kidney is gently submerged in the solution A and stored for 24 hours. After 24 hours, kidney is removed and the biochemical, enzymatic, and physiological functions are determined by using ³¹P-NMR and other tests known in the art.

15 B. The kidney are treated in the same way as described in A.

Storage container connected with the attached portable perfusion pump is prepared as in A and the kidney connected via the renal cannula to the perfusion pump. Perfusion is maintained at steady rate of 3 ml per minute. The perfusion is done at 4°C with the solution A.

20 C. The kidney is treated as in A but storage solution A contains 10% of emulsified perfluorocarbon.

D. The kidney is treated as in B but storage solution A contains 10% of emulsified perfluorocarbon.

25 E. The kidney is treated as in A by perfusing it first with solution A at 37°C for 10 minutes, then the temperature is dropped to 4°C and the kidney is transferred to storage container and stored at 4°C in solution A for 24 hours.

30 Under these conditions, the kidney retain its functional and anatomical integrity as evidenced by the biochemical tests and by ³¹P-NMR for about 5 days or longer.

EXAMPLE 8

Preservation of Isolated Spleen for Transplantation

35 This example illustrates the long-term preservation of spleen for transplantation.

- 33 -

container and stored at 4°C in solution A for 24 hours.

Under these conditions, the spleen retains its functional and anatomical integrity as evidenced by the biochemical tests and by ^{31}P -NMR for more than 10 days.

5

EXAMPLE 9

Preservation of Isolated Brain for Transplantation

This example illustrates the long-term preservation of brain for transplantation.

10 A. The left carotid artery is cannulated, and the brain is carefully removed from the rat's skull with care being taken that no injury to the brain occurs and that the cannula is at all time connected to the perfusion pump and the brain is perfused. The brain is first perfused 10 minutes with the physiologic solution at 37°C. The
15 perfusion is then switched to the solution A described in Example 1 and perfused for 10 minutes at 37°C temperature for another 10 minutes. After 10 minutes, the perfusion is switched back to perfusion with solution A. The brain is submitted to ^{31}P -NMR analysis as described in Example 2.

20 Isolated brain with constant perfusion going on is then transferred extremely carefully to the storage container having a soft support on which the brain rests and which is filled with solution A and maintained at 4°C as shown in Figure 1B. Care is taken that the carotid artery cannula is
25 completely submerged and immediately connected to perfusion pump.

Prior to the organ transfer the container is preoxygenated with filtered mixture of oxygen and carbon dioxide 95/5% from the gas tank source kept outside of
30 container. The container and the solution are kept aseptic at any time.

The brain are gently submerged in the solution A and stored for 24 hours. After 24 hours, brain is removed and the biochemical under constant perfusion and physiological
35 functions are determined by using ^{31}P -NMR.

- 35 -

CLAIMS:

1. A cardioplegic preservation solution suitable for long-term preservation of the heart for transplantation, comprising pyruvate, inorganic salts providing ions to retain the heart cell action potential across the membrane, and a protein selected from the group consisting of albumin, fetal calf serum, or other protein providing viscosity similar to albumin.
2. The solution of Claim 1 wherein the inorganic salts providing the ions are sodium chloride, potassium chloride, calcium chloride, sodium bicarbonate, sodium ethylenediaminetetraacetic acid, magnesium salt.
3. The solution of Claim 2 wherein the protein is fetal calf serum, synthetic or natural albumin, and magnesium salt is magnesium chloride or magnesium sulfate.
4. The solution of Claim 3 comprising 90-120 mM of sodium chloride, 4-4.5 mM of potassium chloride, 0.5-2.5 mM of calcium chloride, 22-28 mM of sodium bicarbonate, 0.0.5 mM of sodium ethylenediaminetetraacetic acid, 0.8-2 mM of magnesium sulfate or magnesium chloride, 6-15 mM of pyruvate and 0.01-1% of fetal calf serum or albumin.
5. The solution of Claim 4 comprising 110 mM of sodium chloride, 4.3 mM of potassium chloride, 2 mM calcium chloride, 25 mM sodium bicarbonate, 0.5 mM of sodium ethylenediaminetetraacetic acid, 1.2 mM of magnesium sulfate, 10 mM of sodium pyruvate and 0.1% of fetal calf serum.

- 37 -

11. A method for preservation of the heart for transplantation comprising perfusion of the heart with a cardioplegic solution comprising 90-120 mM of sodium chloride, 4-4.5 mM of potassium chloride, 0.5-2.5 mM of calcium chloride, 22-28 mM of sodium bicarbonate, 0.0.5 mM of sodium ethylenediaminetetraacetic acid, 0.8-2 mM of magnesium sulfate or magnesium chloride, 6-15 mM of pyruvate, and 0.01-1% of fetal calf serum or albumin.

12. A method for preservation of the heart for transplantation comprising of first perfusion of the heart with cardioplegic solution containing pyruvate at 37°C, followed with a perfusion of the heart with a cardioplegic solution containing pyruvate and ethanol at temperature from 4-37°C and storing the heart in a cardioplegic solution containing pyruvate at temperature between 2-10°C.

13. An organ preservation solution suitable for long-term preservation of liver, kidney, spleen, heart-lung, pancreas, cartilage, skin and cornea for transplantation, comprising pyruvate, inorganic salts providing ions to retain the cell action potential across the membrane and a protein selected from the group consisting of albumin and fetal calf serum.

14. The solution of Claim 13 wherein the inorganic salts providing the ions are sodium chloride, potassium chloride, calcium chloride, sodium bicarbonate, sodium ethylenediaminetetraacetic acid, and magnesium salt.

15. The solution of Claim 14 wherein the protein is fetal calf serum, synthetic or natural albumin, and magnesium salt is magnesium chloride or magnesium sulfate.

- 39 -

21. The solution of Claim 20 comprising 90-120 mM of sodium chloride, 4-4.5 mM of potassium chloride, 0.5-2.5 mM of calcium chloride, 22-28 mM of sodium bicarbonate, 0.0.5 mM of sodium ethylenediaminetetraacetic acid, 0.8-2 mM of magnesium sulfate or magnesium chloride, 6-15 mM of pyruvate 0.1-6% of ethanol and 0.01-1% of fetal calf serum or albumin.

22. A method for preservation of the liver, kidney, spleen, heart-lung, pancreas, cartilage, skin or cornea for transplantation by perfusion of the liver, kidney, spleen, heart-lung, pancreas, cartilage, skin or cornea with a preservation solution comprising 90-120 mM of sodium chloride, 4-4.5 mM of potassium chloride, 0.5-2.5 mM of calcium chloride, 22-28 mM of sodium bicarbonate, 0.0.5 mM of sodium ethylenediaminetetraacetic acid, 0.8-2 mM of magnesium sulfate or magnesium chloride, 6-15 mM of pyruvate, and 0.01-1% of fetal calf serum or albumin.

23. A method for preservation of the liver, kidney, spleen, heart-lung, pancreas, cartilage, skin or cornea for transplantation by perfusion of the liver, kidney, spleen, heart-lung, pancreas, cartilage, skin and cornea with a preservation solution comprising 90-120 mM of sodium chloride, 4-4.5 mM of potassium chloride, 0.5-2.5 mM of calcium chloride, 22-28 mM of sodium bicarbonate, 0.0.5 mM of sodium ethylenediaminetetraacetic acid, 0.8-2 mM of magnesium sulfate or magnesium chloride, 6-15 mM of pyruvate, 0.1-6% of ethanol, and 0.01-1% of fetal calf serum or albumin.

1/6

Perfusion
Chamber





FIGURE 1A

FIGURE 1B



Pressure
Transducer

AMPLIFIER

Microsyringe




FIGURE 1C




FIGURE 3A





FIGURE 3B

5/6



INTERNATIONAL SEARCH REPORT

International Application No. **PCT/US90/07569**

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC(5): A01N 1/02 U.S. CL.: 435/1						
II. FIELDS SEARCHED <div style="text-align: center; margin-top: 10px;">Minimum Documentation Searched ⁷</div> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr> <th style="width: 25%;">Classification System</th> <th style="width: 75%;">Classification Symbols</th> </tr> <tr> <td style="text-align: center; padding: 10px;">U.S.</td> <td style="text-align: center; padding: 10px;">435/1</td> </tr> </table> <div style="text-align: center; margin-top: 10px;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸</div>			Classification System	Classification Symbols	U.S.	435/1
Classification System	Classification Symbols					
U.S.	435/1					
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹						
Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³				
X	US, A, 4,663,289 (VEECH) 05 May 1987, See col 5, Table II.	1-6, 13-15				
P,X	US, A, 4,959,319 (SKELNIK ET AL.) 25 September 1990 See col. 6, lines 35+.	1-6, 13-15				
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents.</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"Z" document member of the same patent family</p> </div> </div>						
IV. CERTIFICATION						
Date of the Actual Completion of the International Search <div style="text-align: center; padding: 10px;">28 March 1991</div>		Date of Mailing of this International Search Report <div style="text-align: center; padding: 10px; font-size: 1.2em;">22 APR 1991</div>				
International Searching Authority <div style="text-align: center; padding: 10px;">ISA/US</div>		Signature of Authorized Officer <div style="text-align: center; padding: 10px;"> Sam Rosen </div> <div style="text-align: right; padding-top: 10px;">(vsh)</div>				